

# FLT3 (CD135) Antibody (N-term)

Purified Rabbit Polyclonal Antibody (Pab)

Catalog # AP7644A

## Product Information

---

<b>Application</b>	WB, FC, IHC-P, E
<b>Primary Accession</b>	<a href="#">P36888</a>
<b>Reactivity</b>	Human, Rat, Mouse
<b>Host</b>	Rabbit
<b>Clonality</b>	Polyclonal
<b>Isotype</b>	Rabbit IgG
<b>Calculated MW</b>	112903
<b>Antigen Region</b>	33-64

## Additional Information

---

<b>Gene ID</b>	2322
<b>Other Names</b>	Receptor-type tyrosine-protein kinase FLT3, FL cytokine receptor, Fetal liver kinase-2, FLK-2, Fms-like tyrosine kinase 3, FLT-3, Stem cell tyrosine kinase 1, STK-1, CD135, FLT3, CD135, FLK2, STK1
<b>Target/Specificity</b>	This FLT3 (CD135) antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 33-64 amino acids from the N-terminal region of human FLT3 (CD135).
<b>Dilution</b>	WB~~1:2000 FC~~1:10~50 IHC-P~~1:100~500 E~~Use at an assay dependent concentration.
<b>Format</b>	Purified monoclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein G column, followed by dialysis against PBS.
<b>Storage</b>	Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
<b>Precautions</b>	FLT3 (CD135) Antibody (N-term) is for research use only and not for use in diagnostic or therapeutic procedures.

## Protein Information

---

<b>Name</b>	FLT3
<b>Synonyms</b>	CD135, FLK2, STK1
<b>Function</b>	Tyrosine-protein kinase that acts as a cell-surface receptor for the cytokine

FLT3LG and regulates differentiation, proliferation and survival of hematopoietic progenitor cells and of dendritic cells. Promotes phosphorylation of SHC1 and AKT1, and activation of the downstream effector MTOR. Promotes activation of RAS signaling and phosphorylation of downstream kinases, including MAPK1/ERK2 and/or MAPK3/ERK1. Promotes phosphorylation of FES, FER, PTPN6/SHP, PTPN11/SHP-2, PLCG1, and STAT5A and/or STAT5B. Activation of wild-type FLT3 causes only marginal activation of STAT5A or STAT5B. Mutations that cause constitutive kinase activity promote cell proliferation and resistance to apoptosis via the activation of multiple signaling pathways.

#### Cellular Location

Membrane; Single-pass type I membrane protein. Endoplasmic reticulum lumen. Note=Constitutively activated mutant forms with internal tandem duplications are less efficiently transported to the cell surface and a significant proportion is retained in an immature form in the endoplasmic reticulum lumen. The activated kinase is rapidly targeted for degradation

#### Tissue Location

Detected in bone marrow, in hematopoietic stem cells, in myeloid progenitor cells and in granulocyte/macrophage progenitor cells (at protein level). Detected in bone marrow, liver, thymus, spleen and lymph node, and at low levels in kidney and pancreas. Highly expressed in T-cell leukemia


## Background

Protein kinases are enzymes that transfer a phosphate group from a phosphate donor, generally the  $\gamma$  phosphate of ATP, onto an acceptor amino acid in a substrate protein. By this basic mechanism, protein kinases mediate most of the signal transduction in eukaryotic cells, regulating cellular metabolism, transcription, cell cycle progression, cytoskeletal rearrangement and cell movement, apoptosis, and differentiation. With more than 500 gene products, the protein kinase family is one of the largest families of proteins in eukaryotes. The family has been classified in 8 major groups based on sequence comparison of their tyrosine (PTK) or serine/threonine (STK) kinase catalytic domains. The tyrosine kinase (TK) group is mainly involved in the regulation of cell-cell interactions such as differentiation, adhesion, motility and death. There are currently about 90 TK genes sequenced, 58 are of receptor protein TK (e.g. EGFR, EPH, FGFR, PDGFR, TRK, and VEGFR families), and 32 of cytosolic TK (e.g. ABL, FAK, JAK, and SRC families).


## References

- Minami, Y., et al., Blood 102(8):2969-2975 (2003).  
Zwaan, C.M., et al., Blood 102(7):2387-2394 (2003).  
Sitnicka, E., et al., Blood 102(3):881-886 (2003).  
Galimberti, S., et al., Anticancer Res. 23(4):3419-3426 (2003).  
Kottaridis, P.D., et al., Leuk. Lymphoma 44(6):905-913 (2003).


## Images



FLT3 (CD135) Antibody (N-term) (Cat. #AP7644a) flow cytometric analysis of 293 cells (right histogram) compared to a negative control cell (left histogram). FITC-conjugated goat-anti-rabbit secondary antibodies were used for the analysis.



Western blot analysis of anti-FLT3 Pab (Cat. #AP7644a) in HL-60 cell lysate. FLT3 (arrow) was detected using purified Pab. Secondary HRP-anti-rabbit was used for signal visualization with chemiluminescence.



Formalin-fixed and paraffin-embedded human cancer tissue reacted with the primary antibody, which was peroxidase-conjugated to the secondary antibody, followed by DAB staining. This data demonstrates the use of this antibody for immunohistochemistry; clinical relevance has not been evaluated. BC = breast carcinoma; HC = hepatocarcinoma.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.